Latest AstraZeneca News | Page 3

Imfinzi plus Imjudo demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four…
Researchers develop a new approach to scale-up manufacturing of life-saving oligonucleotide therapeutics
AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health
‘The dirty disease’ – both smokers and non-smokers get lung cancer. They face stigma on top of illness
Xigduo XR approved in China for adults with type-2 diabetes
Soliris recommended for approval in the EU by CHMP for children and adolescents with refractory generalised myasthenia gravis (gMG)
TGA Product Information safety updates 23 June
Shane Jones: World Health Organisation needs reform – not fattening
Real-world evidence highlights the urgent need to act on the growing global burden of chronic kidney disease
AZD0466 clinical data presented by AstraZeneca at international congress
Soliris approved in China for treatment of adults with refractory generalised myasthenia gravis
Capivasertib in combination with Faslodex granted Priority Review in the US for patients with advanced HR-positive breast cancer
AstraZeneca announces agreement with Quell Therapeutics to develop, manufacture and commercialise engineered T-regulatory cell therapies for autoimmune diseases
Nirsevimab unanimously recommended by FDA Advisory Committee for the prevention of RSV lower respiratory tract disease in infants
Datopotamab deruxtecan combinations showed encouraging tumour responses in patients with advanced non-small cell lung cancer in TROPION-Lung02 Phase Ib trial
Enhertu demonstrated clinically meaningful and durable responses in patients across multiple HER2-expressing advanced solid tumours
Product Information safety updates – April and May 2023
Tagrisso achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial
Lynparza and Imfinzi combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian…
Update on brazikumab development programme
Lynparza plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
Ultomiris approved in Japan for the prevention of relapses in patients with neuromyelitis optica spectrum disorder (NMOSD)
Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy
AstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023
Tina Turner had a history of high blood pressure and kidney disease. Here’s how one leads to the other
Tagrisso plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial
AstraZeneca showcases scientific advances across rare and malignant haematological conditions at EHA 2023
Ultomiris approved in the EU for adults with neuromyelitis optica spectrum disorder (NMOSD)
Farxiga extended in the US to reduce risk of cardiovascular death and hospitalisation for heart failure to a broader range of patients
Koselugo approved in China for paediatric patients with neurofibromatosis type 1 and plexiform neurofibromas
Update on FDA Advisory Committee vote on Lynparza plus abiraterone for metastatic castration-resistant prostate cancer
Q1 2023 results
Five transport trends in Latin America: insights from our ZEV Community forums
NEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of…
Imfinzi-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell…
AstraZeneca advances its pipeline and highlights progress in immuno-oncology, ADCs, cell therapy and epigenetics at AACR
ECCMID data reinforces AstraZeneca’s commitment to transform protection for the most vulnerable by advancing science in vaccines and immune therapies
Scientists build human lungs in dish to test medicines
Another COVID winter is coming. Is this the calm before another peak?
Update to contractual arrangements between AstraZeneca, Swedish Orphan Biovitrum AB and Sanofi
Lynparza and Imfinzi combination improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without tumour BRCA mutations in DUO-O Phase III trial
Sydney supports extension of educational equity program in schools
Ultomiris recommended for approval in the EU by CHMP for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)
GPs more likely to undercharge than overcharge Medicare
License agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate, completed
Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks
TGA Product Information safety updates 27 March
Calquence granted first regulatory approval in China for adults with previously treated mantle cell lymphoma